UNITED STATES, November 18, 2026 — GeneDx Holdings appointed Everett Cunningham as its next chief executive officer, succeeding Katherine Stueland. The company said the transition was expected to take effect on or before December 15, 2026. RTTNews’ November 18 corporate update reported the leadership change.

GeneDx operates in genetic testing, a field where advances in genomic analysis can help clinicians investigate rare and complex conditions. The incoming chief executive will be expected to guide the company’s commercial strategy, support scientific development and maintain relationships with healthcare providers, patients and investors.

Investors will be watching for details of the leadership team’s priorities, including growth, operational execution and the company’s position in the evolving diagnostics market. Continuity in clinical services and confidence among healthcare partners will also be important during the transition.

Reporting note: This article reflects information available on November 18, 2026. Figures and market prices may change as companies and official agencies release updated information.